Stock Traders Buy High Volume of Mylan N.V. Put Options (NASDAQ:MYL)
Mylan N.V. (NASDAQ:MYL) saw unusually large options trading activity on Friday. Traders purchased 10,527 put options on the stock. This represents an increase of approximately 258% compared to the average volume of 2,942 put options.
In other news, President Rajiv Malik sold 25,000 shares of Mylan N.V. stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the sale, the president now directly owns 799,855 shares in the company, valued at approximately $31,994,200. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Anthony Mauro sold 10,000 shares of Mylan N.V. stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider now owns 140,653 shares in the company, valued at $5,626,120. The disclosure for this sale can be found here. Insiders own 0.69% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in Mylan N.V. by 3,447.5% in the first quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock valued at $1,513,696,000 after buying an additional 37,728,274 shares during the last quarter. Pzena Investment Management LLC bought a new stake in Mylan N.V. during the first quarter valued at $283,158,000. TIAA CREF Investment Management LLC raised its stake in Mylan N.V. by 187.3% in the first quarter. TIAA CREF Investment Management LLC now owns 4,315,668 shares of the company’s stock valued at $168,268,000 after buying an additional 2,813,653 shares in the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management bought a new stake in Mylan N.V. during the second quarter valued at $84,364,000. Finally, Morgan Stanley raised its stake in Mylan N.V. by 82.6% in the first quarter. Morgan Stanley now owns 4,174,499 shares of the company’s stock valued at $162,765,000 after buying an additional 1,888,905 shares in the last quarter. Hedge funds and other institutional investors own 70.19% of the company’s stock.
Mylan N.V. (NASDAQ MYL) opened at 32.92 on Monday. The stock’s 50 day moving average is $38.42 and its 200-day moving average is $39.28. The firm has a market capitalization of $17.64 billion, a price-to-earnings ratio of 32.89 and a beta of 1.27. Mylan N.V. has a 12 month low of $32.77 and a 12 month high of $50.40.
Mylan N.V. (NASDAQ:MYL) last posted its quarterly earnings results on Wednesday, May 10th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.01. Mylan N.V. had a net margin of 4.59% and a return on equity of 23.69%. The company had revenue of $2.72 billion for the quarter, compared to the consensus estimate of $2.81 billion. During the same period last year, the company posted $0.76 EPS. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. Equities analysts anticipate that Mylan N.V. will post $5.16 earnings per share for the current fiscal year.
MYL has been the topic of several recent research reports. Wells Fargo & Company reiterated a “market perform” rating and set a $40.00 target price on shares of Mylan N.V. in a research report on Friday, April 14th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $46.00 target price (down from $48.00) on shares of Mylan N.V. in a research report on Monday, April 17th. Deutsche Bank AG decreased their target price on shares of Mylan N.V. from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Tuesday, April 18th. BMO Capital Markets initiated coverage on shares of Mylan N.V. in a research report on Monday, May 1st. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Mylan N.V. from a “hold” rating to a “sell” rating in a research report on Monday, May 15th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $50.92.
COPYRIGHT VIOLATION NOTICE: “Stock Traders Buy High Volume of Mylan N.V. Put Options (NASDAQ:MYL)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/stock-traders-buy-high-volume-of-mylan-n-v-put-options-nasdaqmyl.html.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.